SecBot SecBot
S-3 ·Filed Mar 2, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
BEARISH
Impact 7/10
Horizonweeks Processed8mo ago SEC0001140361-26-007341
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

Monitor for future prospectus supplements that will disclose specific offering terms. The massive size of this shelf relative to market cap suggests potential for significant dilution. Watch for insider selling patterns and upcoming clinical trial data that could trigger an offering.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.80
T+0 close · Mar 2, 2026 · via day close
Latest settled
−37.71%
T+60 · $2.99
Vs SPY
−48.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $4.80entry
  2. T+1 · 9mo ago +0.42%α −0.34% · $4.82
  3. T+5 · 8mo ago +10.42%α +10.89% · $5.30
  4. T+20 · 8mo ago −25.42%α −21.01% · $3.58
  5. T+60 · 6mo ago −37.71%α −48.03% · $2.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals has filed a shelf registration (S-3) for up to $400 million in securities, including common stock, preferred stock, debt, warrants, or units. This filing signals potential future dilutive capital raises but does not specify immediate issuance. The company is a small-cap biotech with a market cap of $3 million, recently restructuring to extend its cash runway.

Key Financial Metrics

Offering Size
$400.0M

Key Facts

  • Rocket Pharmaceuticals filed an S-3 shelf registration for up to $400,000,000 in securities (common stock, preferred stock, debt, warrants, or units)
  • Market cap is only $3 million, meaning the offering could represent over 13,000% of current market value if fully utilized
  • No specific offering details provided - this is a registration for potential future issuances
  • Company recently implemented a 30% workforce reduction and cut operating expenses by 25% to extend cash runway
  • Company is focused on late-stage gene therapy development for rare diseases with high unmet medical need

Financial Impact

Up to $400 million in potential dilutive capital raises, representing over 13,000% of current $3 million market cap

dilutionmarket capshare countequity value

Risk Factors

  • Extreme dilution risk given shelf size is 13,000%+ of current market cap
  • Biotech clinical trial failure risk for gene therapy programs
  • Potential for opportunistic offering at inflated prices if near-term catalysts boost share price

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001140361-26-007341
Document: ny20066752x1_ex4-4.htm0001140361-26-007341
CONTEXT: 10-Q (2025-11-06)0001193125-25-269474

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026